J2355 HCPCS Level II code: Injection, oprelvekin, 5 mg
J2355 is the HCPCS code for “Injection, oprelvekin, 5 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J2355Injection, oprelvekin, 5 mg
Short description: Oprelvekin injection
HCPCS · United States
Medicare details
The indicators CMS publishes with J2355 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jan 1, 1999
Where J2355 sits
- 1J codesDrugs administered other than orally
- 2Active code J2355Injection, oprelvekin, 5 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J2355 mean?
J2355 is the HCPCS code for “Injection, oprelvekin, 5 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J2355?
CMS lists J2355’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J2355
All J codesJ2327Injection, risankizumab-rzaa, intravenous, 1 mgJ2329Injection, ublituximab-xiiy, 1mgJ2350Injection, ocrelizumab, 1 mgJ2351Injection, ocrelizumab, 1 mg and hyaluronidase-ocsqJ2353Injection, octreotide, depot form for intramuscular injection, 1 mgJ2354Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcgJ2356Injection, tezepelumab-ekko, 1 mgJ2357Injection, omalizumab, 5 mgJ2358Injection, olanzapine, long-acting, 1 mgJ2359Injection, olanzapine, 0.5 mgJ2360Injection, orphenadrine citrate, up to 60 mgJ2361Injection, depemokimab-ulaa, 1 mg